ACU-D1 for HPV lesions in people with HIV
Part of Immune system & allergy, Infections clinical trials.
This trial tests an experimental drug called ACU-D1 for people with HIV who have high-grade abnormal cell growth (HSIL) on their vulva or perianal area. The goal is to see if the drug can help treat these HPV-related lesions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years or older
- You must have HIV
- Your CD4 count must be above 200 cells per milliliter
- Your viral load must be undetectable for at least 3 months
- You must have high-grade abnormal cells (HSIL) on your vulva or perianal area, together measuring at least 3 cm, confirmed by biopsy
- You must be on reliable birth control (if applicable) and not be pregnant or nursing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies 2LPAPI® to see if it helps the body clear high-risk HPV infections in the cervix. It may be an option if you have a current HPV infection with mild/early abnormal cervical findings and can complete follow-up for about a year.
This Phase 2 study tests whether a curcumin (a natural plant compound) cream/gel applied to the cervix can help treat cervical cell changes linked to HPV. It focuses on people with mild (LSIL) or recently treated severe (HSIL) precancer changes, aiming to reduce disease and improve healing.
This study tests whether a chemotherapy cream (5-fluorouracil) applied after heat treatment can better prevent cervical and anal precancers in women with HIV. The goal is to improve outcomes for women in Kenya who test positive for HPV, a virus that can cause cancer.
This study tests different ways to screen for HPV (a virus linked to cervical cancer) in women living with HIV. The goal is to find the best, most practical screening approach to catch cervical problems early.
This trial tests an artesunate ointment to treat high-grade anal precancer (HSIL) in people who do not have HIV. The goal is to see if the ointment can clear the abnormal cells caused by HPV.
This study tests if a probiotic called EXE-346 can help clear anal high-grade squamous intraepithelial lesions (HSIL), a precancerous condition, in people with HIV who are on effective antiretroviral therapy. If you have anal HSIL that wasn't fully removed by biopsy, you may be able to join.
Hear when a new Human Papilloma Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.